Biochem/physiol Actions

PF-03882845 is a potent non-steroidal mineralocorticoid antagonist with and IC₅₀ of 0.755 nM, compared to eplerenone with an IC₅₀ of 109 nM. PF-03882845 was tested in a rat model for renal protection against aldosterone-mediated renal disease, and found to be more potent than eplerenone in suppressing the urinary albumin to creatinine ratio (UACR), a measure of renal fibrosis. The therapeutic index, calculated as the ratio of the EC₅₀ for increasing serum K+ to the EC₅₀ for UACR lowering, was 83.8 for PF-03882845 and 1.47 for eplerenone.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Cytokines & Growth Factors research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.